Feasibility and safety of intravenous tolvaptan administration immediately upon ICU admission after cardiac surgery with cardiopulmonary bypass
Masahiko Narita, Kentaro Shirakura, Eijiro Hikasa, Hana Fukuta, Yuya Tamaru, Tomoki Nakatsu, Takayuki Kadohama, Nobuyuki Akasaka, Hiroyuki Kamiya · 2026
Read Feasibility and safety of intravenous tolvaptan administration immediately upon ICU admission after cardiac surgery with cardiopulmonary bypass by Masahiko Narita, Kentaro Shirakura, Eijiro Hikasa, Hana Fukuta, Yuya Tamaru, Tomoki Nakatsu, Takayuki Kadohama, Nobuyuki Akasaka, Hiroyuki Kamiya (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/openalex-w7212146527.txt.
Description
Masahiko Narita leads a team in Japan that tests a new drip drug for heart surgery patients. The drug helps the body shed water as urine. Heart surgery with a bypass machine leaves many patients with fluid to clear. Proof for the drug in this setting is thin. The team gave it to some patients right on arrival in intensive care, and set them by matched peers who did not get it.
The drug group showed sound early urine flow. Their fluid balance also slid into the red at a calm, steady pace. Salt and mineral shifts in the blood did not rise in the group. No patient in either arm had a sharp drop in kidney work. The same calm held for those whose kidneys were weak to start. The team calls the drug safe to use in this slot.
Catalog record
| CREATOR | Masahiko Narita, Kentaro Shirakura, Eijiro Hikasa, Hana Fukuta, Yuya Tamaru, Tomoki Nakatsu, Takayuki Kadohama, Nobuyuki Akasaka, Hiroyuki Kamiya |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 50 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | OpenAlex / Surgery Today |